Where to buy 25C-NBOMe for sale online

The availability of 25C-NBOMe, a designer drug classified as a research chemical for sale online, has raised significant concerns regarding the ethical practices of certain vendors and the potential risks it poses to public health. While research chemicals play a legitimate role in scientific studies, how they are marketed and sold by some online sellers is problematic.
One of the significant issues surrounding the sale of 25C-NBOMe is the lack of proper regulation and oversight. Many online vendors market this substance without adequate safety guidelines or quality control measures. Buyers are often left in the dark about the purity and dosage of the product they purchase, leading to potential health risks. Without accurate information, users may inadvertently consume dangerous amounts of 25C-NBOMe, risking their well-being.
Furthermore, some online sellers exploit legal loopholes to offer 25C-NBOMe for sale. They often label it as a “research chemical” to avoid legal consequences, even though a growing body of evidence suggests its potential for harm. This practice not only endangers users but also undermines the credibility of legitimate research in chemistry and pharmacology.
Another concerning aspect is the marketing tactics used by these vendors. Some actively promote 25C-NBOMe as a recreational substance rather than a research chemical, which can attract individuals seeking recreational highs. This deliberate misrepresentation raises ethical questions about the responsibility of these sellers and their role in contributing to the misuse of such substances.

Summary

25C-NBOMe, also recognized as Cimbi-82, NBOMe-2C-C, and 2C-C-NBOMe, represents a novel psychedelic compound in the phenethylamine class. It finds its place within the 25x-NBOMe series, a recently unearthed cluster of potent psychedelic substances derived from the 2C-x family.
The nomenclature 25C-NBOMe, an abbreviation for 2C-C-NBOMe, originates from the phenethylamine psychedelic 2C-C. In 2003, it was first uncovered by Ralf Heim at the Free University of Berlin and subsequently explored by a research team at Purdue University, spearheaded by David Nichols. Its radiolabeled form has been scrutinized as a potential ligand for mapping serotonin-2A receptors’ distribution in the brain through positron emission tomography (PET). It appeared on the online research chemical market in 2010, marking the inception of human usage.
The subjective effects of 25C-NBOMe encompass stimulation, open and closed-eye visuals, time distortion, euphoria, and ego dissolution. Comparisons with LSD or DOx are occasionally drawn, though 25C-NBOMe is reputed to elicit more pronounced visual effects and exhibit fewer cognitive and emotional aspects like ego dissolution and introspection. Furthermore, it stands out for its heightened stimulating attributes compared to other psychedelics. However, the consumption 25C-NBOMe is linked to more prevalent severe side effects, such as nausea, muscle tension, anxiety, cardiovascular impacts, and even seizures.
It’s imperative to acknowledge that substances within the NBOMe series are not orally active and are typically administered sublingually, absorbed by holding them in the mouth for approximately 15 minutes. Alternatively, some opt for vaporization and inhalation to achieve more immediate and potent effects, albeit with a shorter duration. However, this method is strongly discouraged due to the inherent challenges in measuring and handling microgram-range substances, significantly elevating the risk of overdose. Notably, 25C-NBOMe is occasionally misrepresented as counterfeit LSD due to its similar effects and ability to be laid onto blotter paper.
Our understanding of 25C-NBOMe’s pharmacological properties, metabolism, and toxicity remains limited. Nonetheless, its association with numerous fatalities and hospitalizations suggests a markedly worse toxicity profile than classical psychedelics like LSD or psilocybin mushrooms. With its susceptible dose-response and unpredictable effects, reports imply that using this substance safely can be exceedingly challenging. Therefore, harm reduction practices are strongly recommended for those considering its use.

Chemistry

25C-NBOMe, or 2C-C-NBOMe, belongs to the serotonergic N-benzyl class of substances deriving from the substituted phenethylamine psychedelic compound 2C-C. Its chemical structure features methoxy groups (CH3O-) attached to carbons R2 and R5 and a chlorine atom affixed to carbon R4. A distinctive structural divergence from 2C-C lies in substituting the amine (NH2), wherein a 2-methoxybenzyl (BOMe) group is incorporated, as visually depicted in the accompanying image. This 2-methoxybenzyl (BOMe) substitution is a common characteristic shared by various compounds within the NBOMe family, characterized by a methoxy ether (CH3O-) linked to a benzene ring at the R2 position.

Pharmacology

25C-NBOMe exhibits significant activity at the 5-HT2A receptor, functioning as a potent partial agonist. Nevertheless, the precise mechanisms underlying these interactions and their implications in shaping the psychedelic encounter remain enigmatic.
Compared to its precursor, 2C-C, introducing an NBOMe moiety to the chemical structure yields a sixteen-fold escalation in potency. This heightened potency enables even exceedingly large doses to be accommodated in liquid form on tabs and blotter paper, a factor that frequently leads to misconceptions of it being LSD. However, when juxtaposed with LSD, it possesses only one-third of the potency.

Subjective effects

Disclaimer: The ensuing effects detailed below are derived from the Subjective Effect Index (SEI), which relies on anecdotal user reports and insights from contributors to PsychonautWiki. As such, these effects should be approached with caution and skepticism.

It’s also essential to understand that these effects may not consistently manifest predictably or reliably, although they are more likely to emerge with higher doses. Conversely, escalating doses can heighten the probability of encountering adverse effects, including addiction, severe harm, or even fatality ☠.

Physical:

• Stimulation: 25C-NBOMe is renowned for its considerable energy and stimulation. This physical stimulation resembles 2C-B and is often described as simultaneously laid-back and physically demanding. Sometimes, it may lead to overstimulation, resulting in trembling and teeth grinding. While the levels of stimulation surpass those of classical psychedelics, they remain milder than 25I-NBOMe, which is perceived as somewhat sedating by comparison.
• Mouth Numbing: Upon sublingual consumption, the initial noticeable effect is a strong, unpleasant metallic taste accompanied by significant numbness of the tongue and mouth. This sensation can persist for up to an hour after ingesting the blotter paper. This distinction is crucial for distinguishing between LSD and NBOMe series substances.
• Temperature Regulation Suppression
• Spontaneous Bodily Sensations: Often characterized as a gentle, pervasive, euphoric tingling sensation, the body high is accompanied by occasional waves of euphoria, which become more pronounced as the dosage increases.
• Perception of Bodily Lightness: 25C-NBOMe consistently imparts a sensation of extreme lightness, bordering on weightlessness.
• Tactile Hallucination
• Changes in Felt Gravity: While this effect is less intense than what’s typically associated with DMT and psilocin, it’s still notable compared to classic tryptamines.
• Nausea: Nausea can manifest during the initial come-up, occasionally leading to vomiting. However, this symptom usually subsides once the trip entirely takes hold. In contrast to other psychedelics like psilocin, LSD, 2C-E, and 2C-I, the nausea is relatively mild.
• Abnormal Heartbeat
• Increased Heart Rate
• Increased Blood Pressure
• Muscle Contractions
• Muscle Cramps
• Muscle Tension
• Gustatory Hallucination
• Vasoconstriction
• Appetite Suppression
• Stomach Cramps
• Dehydration
• Dry Mouth
• Difficulty Urinating or Frequent Urination
• Restless Legs
• Pupil Dilation
• Headaches
• Seizures

Visual:

• Enhancements
• Color Enhancement
• Pattern Recognition Enhancement
• Visual Acuity Enhancement
• Distortions: Including drifting (melting, flowing, breathing, and morphing), after-images, color shifting, diffraction, environmental cubism, recursion, scenery slicing, symmetrical texture repetition, tracers, and transformations.
• Geometry: 25C-NBOMe’s visual geometry closely resembles that of LSD, characterized by intricate, algorithmic patterns with fine details, smooth motion, structured shapes, vibrant colors, sharp edges, and rounded corners. These visuals are notably more intricate than those induced by 2C-I and most of the 2C-x family but comparable to LSD, psilocin, and DMT at high doses.
• Hallucinatory States: 25C-NBOMe consistently produces hallucinatory states within the level 1 – 3 range but seldom leads to level 4 – 5 hallucinatory breakthroughs, similar to LSD and 25I-NBOMe. These states encompass internal and external hallucinations of various themes and styles.
• Cognitive:
  • Analysis Enhancement: Primarily observed at low doses.
  • Thought Acceleration and Thought Deceleration: Higher doses may lead to thought deceleration.
  • Conceptual Thinking: Generally mild compared to traditional psychedelics.
  • Anxiety & Paranoia: Occurs more readily, likely due to its pronounced stimulating properties.
  • Feelings of Impending Doom: Typically experienced during the comedown or with large doses.
  • Empathy, Affection, and Sociability Enhancement: Range from mild to robust, often manifesting more firmly in social settings. However, these effects are generally less pronounced than other entactogens like MDMA and 2C-B.
  • Language Suppression
  • Memory Suppression
  • Ego Death
  • Amnesia
  • Novelty Enhancement
  • Immersion Enhancement
  • Emotion Enhancement
  • Increased Sense of Humor
  • Laughter Fits
  • Increased Music Appreciation
  • Personal Bias Suppression
  • Increased Libido
  • Time Distortion
  • Wakefulness

Auditory:

• Enhancements
• Distortions
• Hallucinations

Multi-sensory:

• Dosage Independent Intensity: The reasons for this phenomenon remain unclear, but reports suggest that this substance’s effects can vary significantly even at seemingly identical doses.
• Synaesthesia: A rare and non-reproducible effect, synaesthesia may become more likely with increased dosage, but it primarily affects individuals predisposed to synaesthetic states.

Transpersonal:

• Existential Self-Realization
• Unity and Interconnectedness

Toxicity

25C-NBOMe, a relatively recent addition to the substance landscape, remains shrouded in mystery regarding its pharmacological risks and interactions with other compounds. The precise lethal dose (LD50) is yet undetermined, but it’s known that heavy doses can lead to fatal consequences.

It’s crucial to emphasize that due to its extreme potency, insufflation (snorting) 25C-NBOMe should be strictly avoided, as improper dosing through this method has resulted in several tragic overdose cases.

Hence, it is paramount that harm reduction practices are diligently followed when engaging with this substance.

Dependence and Abuse Potential:

Thankfully, 25C-NBOMe does not foster addiction or habituation; in many cases, users may experience a decreased desire to use it over time. Self-regulation is a typical pattern associated with this compound.

Tolerance and Cross-Tolerance:

Tolerance to the effects of 25C-NBOMe develops almost immediately post-ingestion. Subsequently, it takes around a week for this tolerance to diminish by half, with a total return to baseline occurring after approximately 14 days, assuming no further consumption. It’s worth noting that 25C-NBOMe induces cross-tolerance with all psychedelics, reducing their effects.

Overdose:

The narrow margin between a standard dose and an overdose of NBOMe compounds makes it precarious. The exact toxic dose is unclear, with personal physiology playing a significant role. Dangerous side effects typically emerge when doses exceed 1000 μg and can be life-threatening for more sensitive individuals, possibly around 2000 μg. However, instances of individuals surviving much higher doses, sometimes with minimal side effects, have been reported.

Inaccuracies in blotter paper dosing discourage insufflation, vaporization, or tincture consumption, as these methods have been linked to numerous documented fatalities. A study even found that 25I-NBOMe and 25C-NBOMe blotter papers contain ‘hotspots’ with higher drug concentrations, elevating the risk of overdosing.

Overdose Effects:

NBOMe overdoses typically entail a significantly elevated heart rate, increased blood pressure, hyperthermia, and substantial vasoconstriction. Additionally, overdose symptoms may encompass confusion, delusions, panic attacks, aggressive behavior, numbness or pain, amnesia, and often seizures. The risks of overdosing range from organ failure to cardiac arrest and fatality[citation needed]. Lethal self-injury or fatal falls have also been reported. Medical attention should be promptly sought in a suspected overdose, even in cases involving 25I-NBOMe.

Dangerous Interactions:

It is essential to know that many psychoactive substances considered safe when used individually can become dangerous, even life-threatening, when combined with certain other substances. Due to the highly unpredictable nature of the NBOMe series, it is strongly recommended to avoid mixing them with other psychoactive compounds.

Some notable dangerous interactions include:

• 2C-T-X: These phenethylamines can be unpredictable in their interactions, and when combined with the already unpredictable NBOMes, it’s best to avoid this combination.
• 5-MeO-xxT: The 5-MeO tryptamines can also be unpredictable in their interactions, making them risky when combined with NBOMes.
• Amphetamines: Combining amphetamines with NBOMes can result in tachycardia, hypertension, vasoconstriction, and, in extreme cases, heart failure. The stimulating and focusing effects of amphetamines can exacerbate unpleasant thought loops, and since NBOMes can cause seizures, the risk is higher.
• Caffeine: Caffeine can amplify the natural stimulation induced by psychedelic drugs, making the experience uncomfortable. High doses of caffeine can induce anxiety, which can be challenging to manage during a trip.
• Cannabis: Cannabis can unexpectedly intensify and alter the effects of psychedelics, posing an increased risk of adverse psychological reactions such as anxiety, paranoia, panic attacks, and psychosis. Caution is advised when combining the two, and users should start with a fraction of their usual cannabis dose and take breaks between hits to avoid overconsumption.
• Cocaine: Cocaine and NBOMes both provide substantial stimulation, which, when combined, can lead to severe vasoconstriction, tachycardia, hypertension, and, in severe cases, heart failure.
• DOx: DOx compounds and NBOMes can interact unpredictably, making this combination best avoided.
• DXM: DXM has the potential to interact unpredictably with NBOMes and should be used cautiously when combined.
• Lithium: Combining lithium, commonly prescribed for bipolar disorder, with psychedelics significantly increases the risk of psychosis and seizures, making this combination strictly discouraged.
• MAOIs: MAO-B inhibitors can enhance the potency and duration of phenethylamines unpredictably.
• MDMA: MDMA and NBOMes both provide stimulation, and their combination can result in unpredictable effects, posing physical and mental health risks.
• MXE: As an NMDA antagonist, MXE can intensify the effects of NBOMes, potentially leading to an overly intense experience.
• Tramadol: Tramadol is known to lower the seizure threshold, and NBOMes have shown a tendency to cause severe seizures, making this combination particularly risky.

Always exercise caution and conduct independent research to ensure that combining two or more substances is safe.

Legal status

Austria: As of June 26, 2019, Austria has declared 25C-NBOMe illegal for possession, production, and sale under the SMG (Suchtmittelgesetz Österreich).

Brazil: In Brazil, the possession, production, and sale of 25C-NBOMe are illegal, as listed on Portaria SVS/MS nº 344.

Canada: 25C-NBOMe is categorized as a Schedule III substance in Canada due to its relation to 2,5-dimethoxyphenethylamine.

China: Since October 2015, China has classified 25C-NBOMe as a controlled substance.

Germany: Germany has designated 25C-NBOMe as a controlled substance under Anlage I BtMG (Narcotics Act, Schedule I) since December 13, 2014. Manufacturing, possessing, importing, exporting, buying, selling, procuring, or dispensing without a license is unlawful.

Israel: In Israel, the NBOMe series of psychoactives was brought under regulation in May 2013.

Italy: Italy has classified 25C-NBOMe as a Schedule 1 controlled substance, making it illegal to possess, distribute, or manufacture.

Japan: 25C-NBOMe is considered a narcotic drug in Japan, adequate as of November 1, 2015.

Latvia: 25C-NBOMe is listed as a Schedule I controlled substance in Latvia.

New Zealand: While initially sold as a designer drug in New Zealand in early 2012, 25C-NBOMe was withdrawn from sale following a statement by Associate Health Minister Peter Dunne. It was deemed substantially similar in chemical structure to the illegal hallucinogen DOB and, therefore, classified as a Class C controlled drug analog.

Russia: Russia was the first country to regulate the NBOME class, with the entire NBOMe series of psychoactive becoming controlled in the Russian Federation starting in October 2011.

Sweden: Sweden classifies 25C-NBOMe as Schedule I.

Switzerland: 25C-NBOMe is considered a controlled substance and is named explicitly under Verzeichnis D in Switzerland.

Turkey: Turkey classifies 25C-NBOMe as a drug, making it illegal to possess, produce, supply, or import.

United Kingdom: 25C-NBOMe is categorized as a Class A drug in the United Kingdom, falling under the N-benzyl phenethylamine catch-all clause.

United States: Several NBOMe series compounds, including 25C-NBOMe, 25B-NBOMe, and 25I-NBOMe, will be subject to temporary scheduling in the United States for two years, possibly an additional year.

FAQ

1. What is 25C-NBOMe? 

25C-NBOMe is a synthetic hallucinogenic drug that belongs to the NBOMe family. It is chemically similar to LSD and is known for its potent psychedelic effects.

2. How is 25C-NBOMe typically used? 

It is usually consumed by placing a blotter paper or liquid drop containing the substance on or under the tongue, which is absorbed into the bloodstream.

3. Is 25C-NBOMe legal? 

Laws regarding the legality of 25C-NBOMe vary by country and region. It is considered illegal in many places due to its potential for abuse and health risks.

4. What are the effects of 25C-NBOMe? 

25C-NBOMe can induce strong hallucinations, altered perceptions of reality, and intense sensory experiences. Users may also experience mood swings, anxiety, and increased heart rate.

5. What are the risks associated with 25C-NBOMe use? 

Several risks are associated with 25C-NBOMe use, including overdose, seizures, and dangerous changes in heart rate and blood pressure. It can also lead to psychological distress and long-term mental health issues.

6. Is 25C-NBOMe addictive? 

While 25C-NBOMe is not considered physically addictive, it can be psychologically habit-forming. Users may desire to use it repeatedly to experience its hallucinogenic effects.

7. Can 25C-NBOMe be used safely? 

Using 25C-NBOMe is not safe, as it carries significant health risks. Even in moderate doses, it can lead to unpredictable and adverse reactions.

8. What are the signs of 25C-NBOMe overdose? 

Signs of overdose may include extreme confusion, agitation, seizures, hallucinations, rapid heartbeat, high blood pressure, and even death. If someone shows these symptoms after using 25C-NBOMe, seek medical help immediately.

9. Is there a safe dose of 25C-NBOMe? 

There is no safe dose of 25C-NBOMe, as its effects can vary significantly from person to person. Any use of this substance carries a significant risk of harm.

10. Can 25C-NBOMe cause long-term health issues? 

Long-term use of 25C-NBOMe can potentially lead to mental health issues such as anxiety, depression, and flashbacks. It can also put a strain on the cardiovascular system.

11. Is it possible to test for 25C-NBOMe use in drug tests? 

Standard drug tests typically do not screen for 25C-NBOMe. However, specialized tests may detect its presence if specifically requested.

12. Can 25C-NBOMe be used recreationally? 

Using 25C-NBOMe for recreational purposes is discouraged due to its unpredictable effects and health risks. It is not a safe substance to experiment with.

13. Is there a treatment for 25C-NBOMe addiction or overdose? 

Treatment for 25C-NBOMe overdose may involve supportive care, such as managing symptoms and stabilizing vital signs. Addiction treatment may include counseling and therapy to address underlying issues.

14. Is 25C-NBOMe the same as LSD (acid)? 

While 25C-NBOMe shares some similarities with LSD regarding hallucinogenic effects, it is a different chemical compound and is generally considered more potent and risky.

15. Can 25C-NBOMe be used responsibly and safely? 

Given the potential for severe and unpredictable side effects, responsible and safe use of 25C-NBOMe is not recommended. It is best to avoid this substance altogether.

16. Is there a risk of addiction with 25C-NBOMe? 

While 25C-NBOMe may not be physically addictive, it can lead to psychological dependence in some individuals who repeatedly use it to achieve its hallucinogenic effects.

17. How can I help someone who is using 25C-NBOMe? 

If you suspect someone is using 25C-NBOMe and may be at risk, encourage them to seek help from a medical professional or addiction counselor. Offer your support and guidance without judgment.

18. Is 25C-NBOMe used for any legitimate medical purposes? 

No, 25C-NBOMe is not used for legitimate medical purposes or approved for medical use.

19. What are some street names for 25C-NBOMe? 

Street names for 25C-NBOMe can vary, but some familiar names include “N-Bomb,” “Smiles,” and “25C.”

20. Is it safe to mix 25C-NBOMe with other substances? 

Mixing 25C-NBOMe with other substances, including alcohol and other drugs, can be extremely dangerous and increase the risk of adverse reactions, overdose, and harm.

21. Is 25C-NBOMe research legal? 

Researching 25C-NBOMe may be subject to legal restrictions in many countries due to its status as a controlled or illicit substance. Researchers must adhere to applicable laws and regulations.

22. What should I do if I accidentally ingest 25C-NBOMe? 

If you suspect accidental ingestion of 25C-NBOMe or experience any adverse effects, seek immediate medical attention, as it can be life-threatening.

23. Is 25C-NBOMe ever used in a therapeutic or spiritual context? 

While some individuals may attempt to use 25C-NBOMe for spiritual or therapeutic purposes, it is not recommended, and there is no established tradition or therapeutic framework for its use in this manner.

24. What is the legal status of 25C-NBOMe in different countries? 

The legal status of 25C-NBOMe varies from country to country and even within different regions of the same country. Researching and understanding the specific laws in your area regarding this substance is essential.

25. Where can I find help or support for 25C-NBOMe-related issues? 

If you or someone you know is struggling with 25C-NBOMe use or its consequences, consider contacting a medical professional, addiction counselor, or a helpline dedicated to substance abuse and mental health. Support is available to help individuals address their concerns and seek treatment if needed.

References

1. Erowid 2C-C-NBOMe (25C-NBOMe) Vault: Fatalities / Deaths
2. Heim, R. (2004). “Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2 -Methoxybenzyl-Partialstruktur: Entwicklung eines neuen Struktur-Wirkungskonzepts”. doi:10.17169/refubium-16193.
3. Braden, M. R. (1 January 2007). “Towards a biophysical understanding of hallucinogen action.” Theses and Dissertations Available from ProQuest: 1–176. Retrieved 8 August 2012.
4. Ettrup, A., Hansen, M., Santini, M. A., Paine, J., Gillings, N., Palner, M., Lehel, S., Herth, M. M., Madsen, J., Kristensen, J., Begtrup, M., Knudsen, G. M. (April 2011). “Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT2A agonist PET tracers”. European Journal of Nuclear Medicine and Molecular Imaging. 38 (4): 681–693. doi:10.1007/s00259-010-1686-8. ISSN 1619-7070.
5. Hansen, M. (2010). Design and Synthesis of Selective Serotonin Receptor Agonists for Positron Emission Tomography Imaging of the Brain: Ph.D. Thesis. Faculty of Pharmaceutical Sciences, University of Copenhagen. ISBN 9788792719003.
6. Hansen, M., Phonekeo, K., Paine, J. S., Leth-Petersen, S., Begtrup, M., Bräuner-Osborne, H., Kristensen, J. L. (19 March 2014). “Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists”. ACS Chemical Neuroscience. 5 (3): 243–249. doi:10.1021/cn400216u. ISSN 1948-7193.
7. Zuba, D., Sekuła, K., Buczek, A. (10 April 2013). “25C-NBOMe–new potent hallucinogenic substance identified on the drug market”. Forensic Science International. 227 (1–3): 7–14. doi:10.1016/j.forsciint.2012.08.027. ISSN 1872-6283.
8. Erowid 2C-C-NBOMe Vault: Dose/Dosage
9. Tarpgaard, M., Mærkedahl, R., Lauridsen, K. B. (24 August 2015). “[Fatal intoxication with the new designer drug 25C-NBOMe]”. Ugeskrift for Laeger. 177 (35): V09140523. ISSN 1603-6824.
10. Grautoff, S., Kähler, J. (May 2014). “[Near fatal intoxication with the novel psychoactive substance 25C-NBOMe]”. Medizinische Klinik, Intensivmedizin Und Notfallmedizin. 109 (4): 271–275. doi:10.1007/s00063-014-0360-5. ISSN 2193-6226.
11. Erowid 25I-NBOMe (2C-I-NBOMe) Vault: Fatalities / Deaths
12. Erowid NBOMe (Other or Unknown NBOMe-Compound) Vault: Fatalities / Deaths
13. Lützen, E., Holtkamp, M., Stamme, I., Schmid, R., Sperling, M., Pütz, M., Karst, U. (April 2020). “Multimodal imaging of hallucinogens 25C‐ and 25I‐NBOMe on blotter papers”. Drug Testing and Analysis. 12 (4): 465–471. doi:10.1002/dta.2751. ISSN 1942-7603.
14. Marchi, N. C., Scherer, J. N., Fara, L. S., Remy, L., Ornel, R., Reis, M., Zamboni, A., Paim, M., Fiorentin, T. R., Wayhs, C. A. Y., Von Diemen, L., Pechansky, F., Kessler, F. H. P., Limberger, R. P. (1 March 2019). “Clinical and Toxicological Profile of NBOMes: A Systematic Review.” Psychosomatics. 60 (2): 129–138. doi:10.1016/j.psym.2018.11.002. ISSN 0033-3182.
15. Yoon, K. S., Yun, J., Kim, Y.-H., Shin, J., Kim, S. J., Seo, J.-W., Hyun, S.-A., Suh, S. K., Cha, H. J. (1 April 2019). “2-(2,5-Dimethoxy-4-methylphenyl)-N-(2-methoxybenzyl)ethanamine (25D-NBOMe) and N-(2-methoxybenzyl)-2,5-dimethoxy-4-chlorophenethylamine (25C-NBOMe) induce adverse cardiac effects in vitro and in vivo”. Toxicology Letters. 304: 50–57. doi:10.1016/j.toxlet.2019.01.004. ISSN 0378-4274.
16. Image: Nbome_death_news_i2013e0190_disp.jpg (Source: psychonautwiki.org)
17. Image: Nbome_death_news_i2013e0191_disp.jpg (Source: psychonautwiki.org)
18. Austria: https://www.ris.bka.gv.at/Dokumente/BgblAuth/BGBLA_2019_II_167/BGBLA_2019_II_167.pdfsig
19. Brazil: http://portal.anvisa.gov.br/documents/10181/3115436/%281%29RDC_130_2016_.pdf
20. Canada: Consolidated federal laws of Canada, Controlled Drugs and Substances Act
21. China: 关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | http://www.sfda.gov.cn/WS01/CL0056/130753.html
22. Germany: “Achtundzwanzigste Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften” (PDF) (in German). Bundesanzeiger Verlag. Retrieved December 11.